-
Memorial Sloan Kettering Researchers Report Success in Controlling Stubborn Mesothelioma Tumors
For more than two years, researchers from the renowned Memorial Sloan Kettering Cancer Center in New York have been studying whether the cancer drug Tazemotostat could inhibit the growth of malignant mesothelioma tumors. At the 2020 ASCO Annual Meeting, they presented data showing that it successfully inactivated the effect of the BAP1 gene mutation and
-
Japanese Study Reveals Vital Data Regarding Common Mesothelioma Surgery
Patients with malignant pleural mesothelioma go through a rigorous staging and assessment protocol once their cancer has been diagnosed. The goal is to determine how advanced their cancer is, what their overall health status is and where the tumors are so that the best possible treatment plan can be put in place. One of the
-
NJ Supreme Court Places Mesothelioma Liability for Replacement Parts on Original Manufacturers
For years, manufacturers of automobiles and other pieces of equipment requiring replacement parts have denied their responsibility for malignant mesothelioma caused by asbestos in replacement parts for their equipment. They have pointed to the parts manufacturers and tried to wash their hands of responsibility despite the fact that their equipment required those parts to continue
-
Court Denies Crane’s Motion to Dismiss Maritime Laws in Mesothelioma Claim
There’s little question that Navy veteran Herbert H. Mullinex’s malignant mesothelioma comes from exposure to asbestos during his service. He worked on several ships doing shipbuilding and repair. In suing John Crane, Inc., he did so under both federal and maritime law. Though the company has not argued that their product was not responsible, they
-
ASCO20 Virtual Scientific Program Continues to Reveal Progress in Mesothelioma Treatment
This year’s American Society of Clinical Oncology’s meeting had to be held virtually in light of the global pandemic, but that has in no way interfered with the revelations of remarkable progress in the treatment of malignant pleural mesothelioma. Among the presentations was news that Italian researchers have significantly improved survival among mesothelioma patients by treating
-
Mesothelioma Advocates Criticize EPA Delays on Asbestos
Mesothelioma advocates are criticizing EPA decisions as the agency announces another delay in its evaluation of asbestos and its potential for harm. Blaming the challenges created by the global pandemic, EPA chief Andrew Wheeler informed the Senate Environment and Public Works Committee that it would not be able to meet the statutory deadline of June
-
Mesothelioma Physicians Concerned by Report of Increased COVID-19 Mortality
A study analyzing characteristics of patients with thoracic cancers like malignant mesothelioma who developed COVID-19 revealed that patients who had received chemotherapy within three months of their diagnosis with the virus had a significantly increased risk of death. The information was presented ahead of the 2020 American Society of Clinical Oncology Virtual Scientific Program, and
-
Turkish Research Supports Use of New Radiation Therapeutics for Malignant Pleural Mesothelioma
In the hierarchy of treatments used for malignant mesothelioma, radiation therapy has frequently been ranked the lowest: though it can help to provide symptom relief, it has not generally been credited for extended survival or progression free survival. Now a study out of Turkey has introduced statistics that show the use of innovative targeted therapies
-
ONCOS-102 Plus Chemotherapy Extends Mesothelioma Progression-Free Survival
Though people diagnosed with malignant pleural mesothelioma are told at the outset that their condition is both incurable and fatal, that does nothing to stop them from pinning their hopes on innovative medical treatments. Some of those hopes may be fulfilled, as a recent test of a genetically modified virus has proven capable of infecting
-
Scientists Call Mesothelioma Survival Following Immunotherapy and Chemotherapy Combination “Remarkable”
The results are in from a phase II study that tested a combination of standard chemotherapy with a new immunotherapy drug on patients diagnosed with malignant mesothelioma, and the results have been described as “remarkable.” The immunotherapy drug is durvalumab (brand name Infinzi) and it was developed by Medimmune/AstraZeneca. The results will be presented at
-
What Malignant Mesothelioma and COVID-19 Have in Common
If you have a known exposure to asbestos, whether from the workplace, exposure to a family member who worked with the substance, or some other source, you have long been aware of your risk for malignant mesothelioma, asbestosis, and other asbestos-related diseases. As if those fears were not stressful enough, those same individuals are now
-
Facing Thousands of Mesothelioma Lawsuits, Johnson & Johnson Talc Provider Strikes Settlement Deal
While multi-million-dollar mesothelioma lawsuits against Johnson & Johnson’s Baby Powder have been capturing headlines, litigation against the company’s talc provider Imerys led the smaller organization to file for bankruptcy last year. This week they announced that they will be selling their North American operations and using the assets to settle more than 14,000 lawsuits against
-
Facing Thousands of Mesothelioma and Ovarian Cancer Lawsuits, Johnson & Johnson Announces End to Talc Baby Powder Sales
In the face of thousands of lawsuits accusing their product of causing malignant mesothelioma and ovarian cancer, Johnson & Johnson has announced that they will no longer sell their talc-based baby powder product in the United States or Canada. The product has long been one of the world’s most recognizable and trusted consumer products.
-
Experts Point to Climate Change’s Impact on Cancers Like Malignant Mesothelioma
Malignant mesothelioma is an asbestos-related disease that is traditionally (and appropriately) associated with occupational settings. Most victims are those who have been exposed to the carcinogen in factories, in high-heat settings like boiler rooms, and while working on construction sites doing insulation work, working with asbestos concrete, and ceiling and floor tile installation or removal.
-
Italian Researchers Find Silencing Gene May Help Slow Mesothelioma
For researchers investigating malignant mesothelioma, any progress — no matter how incremental — is to be celebrated. The disease has proven remarkably resistant to treatment, so when scientists identify a way to slow the rare form of cancer’s spread it is notable. Such is the case of a recent discovery by Italian researchers that is detailed
-
Fasting-Mimicking Diet Combined with Vitamin C Shows Promise Against Genetic Mutation Found in Mesothelioma
Malignant mesothelioma is one of the most challenging types of cancer to treat. This is partially due to the disease not being diagnosed until it is in an advanced stage, and partially due to its extreme resistance to chemotherapy. That resistance has been linked to a variety of genetic mutations including a mutation in the
-
International Cancer Group Issues COVID-19 Guidance Helpful to Mesothelioma Patients
COVID-19 has struck fear into the hearts of people all over the world, but perhaps none as much as those at high risk due to serious illnesses like malignant mesothelioma. Cancer patients are not only generally more vulnerable to disease: they also rely upon regular medical treatment, and going for those treatments in the presence
-
Study Show that Shipbuilders’ Elevated Mesothelioma Risk in America is Echoed In Nordic Countries
The United States sees an average of 3,500 people diagnosed with malignant mesothelioma each and every year, and a large proportion of those who have the disease are able to track their asbestos exposure to their days working on ships or in actually building seagoing vessels. That trend is not unique to the United States,
-
Mesothelioma Treatment, Clinical Trials Impacted by COVID-19
All around the country people’s lives have been turned upside down by COVID-19, but perhaps none so much as those who were already dealing with the unthinkable — a mesothelioma diagnosis. Where the rest of us are rightly concerned about jobs lost or put on hold, separation from family members and friends, and the availability of
-
Spanish Mesothelioma Study Shows Improved Progression Free Survival
For those diagnosed with malignant mesothelioma, an additional few months of feeling good and being able to maintain a normal quality of life is a great gift, and that is what researchers from Madrid’s 12 de Octubre University Hospital are seeing from their testing of a new first-line treatment called ONCOS-102. According to principal investigator Luis
